Peptide side effects: what the research shows
Peptide side effects depend on the compound. Approved peptide drugs such as tesamorelin and semaglutide have published safety data from large trials. Most research peptides sold for laboratory use do not. This guide summarises what published reviews report. Research peptides are sold for laboratory use only.
| Peptide | What the sources report on safety | Evidence base |
|---|---|---|
| BPC-157 | A 2025 systematic review found 35 preclinical studies and 1 clinical study. Preclinical safety studies showed no adverse effects across several organ systems, but no clinical safety data were found (Vasireddi 2025) | Animal studies, one small clinical report |
| Tesamorelin | In a 52-week extension of randomised trials in HIV patients, tesamorelin was generally well tolerated, and glucose changes were not clinically significant (Falutz 2008) | Phase 3 trials (approved drug) |
| Semaglutide | A 2021 review concludes it mostly causes mild-to-moderate and transient gastrointestinal disturbances and increases the risk of gallstone disease (Smits 2021) | Phase 3 trials (approved drug) |
| Other unapproved peptides (CJC-1295, ipamorelin, TB-500, GHK-Cu and others) | A 2026 review states that many unapproved peptides show favourable results in animal models, but rigorous human safety data are scarce, with potential for serious harm (Mendias 2026) | Narrative review |
Do peptides have side effects?
Yes, where tested. Approved peptide drugs list adverse events in their trials, for example gastrointestinal effects with semaglutide (Smits 2021). For unapproved research peptides, the main finding in the literature is a gap: a 2026 review reports that rigorous human safety data are scarce (Mendias 2026).
Are research peptides safe?
No source checked shows clinical safety for research peptides in humans. A 2025 systematic review of BPC-157 concluded that adverse effects are possible due to unregulated manufacturing, contamination or unknown clinical safety (Vasireddi 2025). Stackpure products are for laboratory research only and are not for human consumption.
Why product quality matters
Part of the safety question is what is in the vial. A published case found a black-market product contained a His-tagged laboratory protein rather than the expected peptide (Kohler 2010). Check the batch certificate of analysis using the supplier checklist, and see lab testing for how Stackpure documents testing.
Frequently Asked Questions
What are the side effects of peptides?
It depends on the compound. Semaglutide mostly causes mild-to-moderate and transient gastrointestinal disturbances (Smits 2021), and tesamorelin was generally well tolerated over 52 weeks (Falutz 2008). For unapproved peptides, human safety data are scarce (Mendias 2026).
What are the side effects of BPC-157?
A 2025 systematic review found no clinical safety data and no adverse effects in preclinical safety studies, and it noted that adverse effects are possible due to unregulated manufacturing, contamination or unknown clinical safety (Vasireddi 2025).
Is tesamorelin safe?
Tesamorelin is an approved drug for HIV-associated abdominal fat. In a 52-week extension of randomised trials it was generally well tolerated (Falutz 2008). Read more in What Is Tesamorelin?
Key References
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PubMed 40756949
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PubMed 41966639
- Falutz J, et al. Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation. AIDS. 2008. PubMed 18690162
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021. PubMed 34305810
- Kohler M, et al. Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Horm IGF Res. 2010. PubMed 20675162
For research use only. Not for human consumption.